Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Iterum Therapeutics (ITRM)
:ITRM
Holding ITRM?
Track your performance easily
ITRM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.81 - $3.02
Previous CloseN/A
Volume220.96K
Average Volume (3M)1.07M
Market Cap
$42.37M
Enterprise Value$30.05M
Total Cash (Recent Filing)$24.81M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.88
Next Earnings
Mar 31, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.00
Shares Outstanding27,515,926
10 Day Avg. Volume624,847
30 Day Avg. Volume1,069,081
Standard Deviation0.37
R-Squared0.11
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.10
Forecast
1Y Price Target
$10.00Price Target Upside549.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Iterum Therapeutics News
PremiumCompany Announcements
Iterum Therapeutics’ Strategic Advances with ORLYNVAH Approval
PremiumMarket News
3 Penny Stocks to Watch Now, 10/29/24
PremiumCompany Announcements
Iterum Therapeutics Gains FDA Approval for ORLYNVAHBulls Say, Bears Say
Bulls Say
Market OpportunityThe uUTI space has a substantial market opportunity with a large population of women at elevated risk, representing over 40 million prescriptions per year.
Regulatory ApprovalThe FDA approved oral sulopenem, brand name ORLYNVAH, for the treatment of uncomplicated urinary tract infections in adult women with limited or no alternative oral antibiotic treatment.
Unmet Medical NeedSulopenem could be the first treatment for uUTI patients with a history of infections with organisms producing extended-spectrum beta-lactamase, reducing risks and costs by shifting to an oral therapy.
Bears Say
Clinical Trial ResultsPrior P3 trials missed on non-inferiority in cipro-susceptible cases.
Market PerformanceIt has been a long road to get here with the CRL for uUTI weighing on ITRM shares, which was further exacerbated by challenging biotech markets.
Regulatory ConcernsSulopenem's use could be more limited than anticipated due to a more restrictive label given the concerns of antimicrobial resistance against carbapenems.
---
Ownership Overview
8.85% Insiders
0.04% Mutual Funds
7.18% Other Institutional Investors
83.93% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ITRM FAQ
What was Iterum Therapeutics’s price range in the past 12 months?
Iterum Therapeutics lowest stock price was $0.81 and its highest was $3.02 in the past 12 months.
What is Iterum Therapeutics’s market cap?
Iterum Therapeutics’s market cap is $42.37M.
When is Iterum Therapeutics’s upcoming earnings report date?
Iterum Therapeutics’s upcoming earnings report date is Mar 31, 2025 which is in 72 days.
How were Iterum Therapeutics’s earnings last quarter?
Iterum Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.175 by -$0.065.
Is Iterum Therapeutics overvalued?
According to Wall Street analysts Iterum Therapeutics’s price is currently Undervalued.
Does Iterum Therapeutics pay dividends?
Iterum Therapeutics does not currently pay dividends.
What is Iterum Therapeutics’s EPS estimate?
Iterum Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Iterum Therapeutics have?
Iterum Therapeutics has 27,515,926 shares outstanding.
What happened to Iterum Therapeutics’s price movement after its last earnings report?
Iterum Therapeutics reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.175. Following the earnings report the stock price went down -4.895%.
Which hedge fund is a major shareholder of Iterum Therapeutics?
Among the largest hedge funds holding Iterum Therapeutics’s share is New Leaf Venture Partners, L.L.C.. It holds Iterum Therapeutics’s shares valued at 376K.
---
Iterum Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (549.35% Upside)
$10.00 (549.35% Upside)
Hedge Fund Trend
Increased
By 247.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.64%
12-Months-Change
Fundamentals
Return on Equity
265.53%
Trailing 12-Months
Asset Growth
-59.92%
Trailing 12-Months
Company Description
Iterum Therapeutics
Iterum Therapeutics Plc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of treatments for drug resistant bacterial infections. It focuses on sulopenem program that offer a solution to the problem of antibiotic resistance, and the toxicity limitations of existing agents. It operates through the Ireland and Unites States geographical segments. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.
---
ITRM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted the significant milestone of receiving FDA approval for ORLYNVAH, along with strong market exclusivity and patent protection. While there were substantial reductions in operating expenses, the increase in net loss and outstanding debts are concerns. Overall, the call leans positively due to the strategic advancements and financial planning to extend the cash runway.Read More>---
ITRM Stock 12 Month Forecast
Average Price Target
$10.00
▲(549.35% Upside)
Technical Analysis
Best Analysts Covering ITRM
1 Year
1 Year Success Rate
5/7 ratings generated profit
1 Year Average Return
+22.56%
reiterated a buy rating 4 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +22.56% per trade.
---